Searchable abstracts of presentations at key conferences in endocrinology

ea0081oc7.5 | Oral Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

Epigenomic and somatic mutation profile of pituitary adenomas (PAs)/ pituitary neuroendocrine tumors (PitNETs)

Guaraldi Federica , Morandi Luca , Zoli Matteo , Righi Alberto , Evangelisti Stefania , Tonon Caterina , Mazzatenta Diego , Asioli Sofia

Background: Pituitary adenomas (PAs)/Pituitary Neuroendocrine Tumors (PitNETs) are a complex and heterogeneous group of lesions. Genetic and epigenetic studies have been performed to identify predictors of treatment outcome.Study aim: To profile clinically non-aggressive (NA) and aggressive (A) PAs/PitNETs, and carcinomas for somatic mutations and epigenetic alterations of genes involved in cell proliferation/differentiation, miRNA/lncRNA-post-transcript...

ea0081p407 | Pituitary and Neuroendocrinology | ECE2022

Endoscopic surgery for acromegaly: results and predictors of outcome from a 22-year experience of a referral Pituitary Centre

Guaraldi Federica , Zoli Matteo , Gori Davide , Cavicchi Riccardo , Pasquini Ernesto , Sollini Giacomo , Asioli Sofia , Mazzatenta Diego

Background: Endoscopic surgery (ES) performed in Pituitary Centers of Excellence (PCOE) represents the gold standard treatment for GH-secreting adenomas. However, rate of cure greatly varies according to definition criteria, follow-up duration, various patient and adenoma features, and surgeon ability.Study aim: To assess short- (3 month) and long-term (≥1 year) outcome and identify predictors of ES, in a large and homogeneous cohort of acromegaly ...

ea0063p1115 | Pituitary and Neuroendocrinology 3 | ECE2019

Pituitary apoplexy occurs more frequently in the morning

Faustini-Fustini Marco , Guaraldi Federica , Zoli Matteo , Asioli Sofia , Mazzatenta Diego , Provini Federica

Pituitary apoplexy (PA) is a rare clinical syndrome due to sudden haemorrhage and/or infarction of the pituitary gland, usually within a pre-existent pituitary tumour. Even though some sporadic cases of PA associated with rare sellar lesions (such as Rathke cleft cysts) have been reported, in the vast majority of cases the syndrome occurs within a pituitary adenoma. At presentation, patients with PA usually complain of sudden and severe headache, often associated with visual l...

ea0032p850 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Endoscopic transsphenoidal approach as a promising surgical option in the treatment of craniopharyngioma

Faustini-Fustini Marco , Zoli Matteo , Mazzatenta Diego , Santi Daniele , Brigante Giulia , Pasquini Ernesto , Frank Giorgio

Introduction: The management of craniopharyngioma (CR) remains a challenge. The introduction of endoscopic technique in the surgical approach to the sellar/suprasellar region would have profound implications for treatment. The aim of the study was to analyze results, advantages and limits of endoscopic endonasal approach (EEA).Design/methods: From 1998 to 2012, 95 patients underwent surgery for CR. Trancranial approach was chosen for 33 patients (35%) on...

ea0022p665 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Transition from Cushing's disease to a hormonally inactive adenoma or vice versa: four unusual cases of corticotroph adenoma

Faustini-Fustini Marco , Zoli Matteo , Mazzatenta Diego , Pasquini Ernesto , Pia Foschini Maria , Granata Antonio , Frank Giorgio

Over the last decade 824 pituitary tumours have been removed in our centre. Of these, 114 (13.8%) were corticotroph adenomas. We present four unusual cases of corticotroph adenoma showing transition from Cushing’s disease to a hormonally inactive adenoma (case 1 and 2) or vice versa (case 3 and 4).Case 1: A 51-year-old man was admitted with a 2-year history of weight gain, arterial hypertension and chiasmatic syndrome. Cushing’s disease (CD) du...

ea0016p482 | Neuroendocrinology | ECE2008

Endoscopic pituitary surgery as the primary treatment for acromegaly: a prospective study in a specialised centre

Faustini-Fustini Marco , Magrini Satima , Anagni Mascia , Mazzatenta Diego , Pasquini Ernesto , Frank Giorgio

The main aims of treatment of acromegaly are reversing symptoms and signs, removing the tumour, preventing disease recurrence, and improving survival. Increased mortality associated with acromegaly can be diminished if treatment is successful in reducing GH <2–2.5 ng/ml. We carried out a prospective study to assess whether recent advances in surgical technique (namely the endoscopic approach in a specialised centre encompassing specialist pituitary surgeons working in...

ea0090p415 | Pituitary and Neuroendocrinology | ECE2023

Synchronous multiple pituitary neuroendocrine tumors (PitNETs) consisting of a null cell and PIT-1 lineage adenomas: a peculiar acromegalic case report

Bruco Alessia , Zoli Matteo , Melotti Sofia , Ribichini Danilo , Pizza Gianmarco , Mao Federico , Mazzatenta Diego , Asioli Sofia , Pagotto Uberto

Pituitary adenomas constitute the third most common intracranial neoplasm. Adenoma cells either express no hormone (null cell adenoma) or hormones of different cell lineage. About 1% of pituitary adenomas shows a plurihormonal expression pattern, which may either be attributed to one cell lineage or rarely to different cell lineages. In addition, the development of separate pituitary adenomas may be observed in 0.5–1.5% of surgical specimens and in up to 10% of autopsy ca...

ea0090p683 | Pituitary and Neuroendocrinology | ECE2023

Association of Pituitary Adenoma (Pa)/Pituitary Neuroendocrine Tumor (Pit-Net) and Cerebral Aneurysm: risk factors, peculiar features and management

Guaraldi Federica , Zoli Matteo , Nawabi Noah , Kilgallon John L. , Gori Davide , Asioli Sofia , Mazzatenta Diego , Richard Smith Tim

Rationale and aim: The incidence of intracranial aneurysms (IA) appears increased in patients with PAs/PitNETs. Changes in hemodynamics and vascular structure secondary to mass effect, inflammation, and hormonal changes (primarily, GH hypersecretion) have been suggested as risk factors. Study aim was to define typical features, timing of occurrence and treatment, and identify risk factors in patients with PA/PitNET and IA.Patients and methods: Data of 57...

ea0037oc12.4 | Pituitary – Clinical | ECE2015

The changing faces of corticotroph-cell adenomas: the role of proconvertase 1/3

Faustini-Fustini Marco , Righi Alberto , Asioli Sofia , Morandi Luca , Zoli Matteo , Mazzatenta Diego , Frank Giorgio , Foschini Maria Pia

Introduction: The possible change in the pattern of hormonal secretion by pituitary tumours is a very intriguing issue indeed, notably in the case of corticotroph-cell adenomas.Methods/design: We retrospectively reviewed the records of 1259 consecutive endoscopic endonasal surgical procedures for pituitary adenomas from 1998 to 2013. Of these, 132 were ACTH-secreting adenomas associated with Cushing’s disease (CD) and 44 were silent corticotroph-cel...

ea0081p401 | Pituitary and Neuroendocrinology | ECE2022

Prevalence, type and evolution of autoimmune diseases with respect to hormone control in patients with cortisol, GH and prolactin hypersecretion

Guaraldi Federica , Zoli Matteo , Arvat Emanuela , De Martin Martina , Pecori Giraldi Francesca , Carla Scaroni , Gori Davide , GIORDANO Roberta , Grottoli Silvia , Ghigo Ezio , Asioli Sofia , Mazzatenta Diego

Background: In vitro and animal experiments have clearly demonstrated that excessive cortisol, GH and prolactin secretion, as well as dopamine agonists (D2As) and somatostatin analogs (SSAs), often prescribed for their treatment, affect the immune response and the onset/evolution of autoimmune diseases (AIDs) through direct and indirect complex mechanisms. Data from clinical studies are very scanty.Study aim: To assess the 1) distribution of AIDs accordi...